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Abstract: Acute vascular endothelial dysfunction is a central event in the pathogenesis of sepsis, 
increasing vascular permeability, promoting activation of the coagulation cascade, tissue edema 
and compromising perfusion of vital organs. Aging and chronic diseases (hypertension, 
dyslipidaemia, diabetes mellitus, chronic kidney disease, cardiovascular disease, cerebrovascular 
disease, chronic pulmonary disease, liver disease, or cancer) are recognized risk factors for sepsis. 
In this article we review the features of endothelial dysfunction shared by sepsis, aging and the 
chronic conditions preceding this disease. Clinical studies and review articles on endothelial 
dysfunction associated to sepsis, aging and chronic diseases published in PubMed were 
considered. The main features of endothelial dysfunction shared by sepsis, aging and chronic 
diseases were: 1) increased oxidative stress and systemic inflammation, 2) glycocalyx degradation 
and shedding, 3) disassembly of intercellular junctions, endothelial cell death, blood–tissue barrier 
disruption, 4) enhanced leukocyte adhesion and extravasation, 5) induction of a pro-coagulant and 
anti-fibrinolytic state. In addition, chronic diseases impair the mechanisms of endothelial 
reparation. In conclusion, sepsis, aging and chronic diseases induce similar features of endothelial 
dysfunction. The potential contribution of the pre-existent degree of endothelial dysfunction to 
sepsis pathogenesis deserves to be further investigated. 
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1. Introduction 
Sepsis is a major health problem worldwide. Data coming exclusively from high-income countries 
suggests that 50.9 million cases of sepsis occur globally each year, with potentially 5.3 million deaths 
annually [1]. Global burden of this disease is thought to be much higher, since data on sepsis 
incidence in low-income and middle-income countries remain scarce. Vascular endothelial 
dysfunction (ED) is a central event in the pathophysiology of sepsis [2]. ED precedes organ 
dysfunction and plays an important role in its pathogenesis by increasing vascular permeability, 
promoting activation of the coagulation cascade, tissue edema and compromising regional perfusion 
in vital organs [3].  
Aging and chronic co-morbidities are recognized risk factors of sepsis. In a recent report from the 
American Centers for Disease Control with 246 sepsis patients, median age was 69 yrs. Most of the 
patients in this study (97%) had at least one co-morbidity. 35% had diabetes mellitus, 32% had 
cardiovascular disease (including coronary artery disease, peripheral vascular disease, or congestive 
heart failure), 23% had chronic kidney disease, and 20% had chronic obstructive pulmonary disease 
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[4]. Two large epidemiological studies on sepsis which already use the new SEPSIS-3 criteria for 
defining this disease provide a similar picture of the clinical characteristics of sepsis patients. The 
studies of Rhee et al with 173 690 patients [5] and Donnelly et al with 1080 patients [6] reveal that the 
mean age of sepsis patients was 66.5 yr and 69.7 yr respectively. In these large reports, the most 
frequent co-morbidities present in sepsis patients were those participating of the metabolic 
syndrome (hypertension, dyslipidaemia, diabetes mellitus), chronic kidney disease, cardiovascular 
disease, cerebrovascular disease, chronic pulmonary or liver disease, and cancer (Table 1). Aging 
and the co-morbidities preceding sepsis are characterized by inducing chronic ED. In consequence, it 
is probably that the acute endothelial injury induced by sepsis in aged / chronic disease patients is 
occurring on an endothelium which is, to a greater or lesser extent, already damaged. 
Rhee et al  
(N = 173690) 
Donnelly et al 
 (N = 1080) 
Age (mean in yrs) 66.5 Age (mean) 69.7 
Sex (male) 57.6% Sex (male) 59.2% 
Diabetes 35.7 % Hypertension 74.5 % 
Chronic pulmonary disease 30.9 % Dyslipidaemia 67.3 % 
Renal disease 26.8 % Diabetes 41.8 % 
Congestive heart failure 25.4 % Chronic kidney disease 31.5 % 
Cancer 19.7 % Myocardial infarction 24.4 % 
Dementia or cerebrovascular disease 10.3 % Chronic Lung disease 17.4 % 
Liver disease 10 % Stroke 12.6 % 
Table 1. Mean age, sex and major co-morbidities associated to sepsis. These data correspond to the 
studies of Rhee et al [5] and Donnelly et al [6]. Co-morbidities are showed by their observed 
prevalence in each study. 
This article identifies five major features of ED shared by sepsis, aging and the chronic diseases 
preceding this severe condition.  
2. Search strategy and selection criteria:  
References for this narrative review were identified through searches of PubMed for articles, giving 
priority to those published in the last 10 years, which constitutes 95% of the articles cited. Terms 
used were “endothelial dysfunction”, “endothelium”, “sepsis”, “aging”, “elderly”, and each one of 
the co-morbidities associated to sepsis. Other terms searched in combination with "endothelial 
dysfunction" were “repair”, “progenitor cells”, “chemotherapy” and “radiotherapy”. 
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3. The healthy endothelium  
The vascular endothelium constitutes a semi-permeable barrier lining the inner surface of blood 
vessels (Figure 1). It controls the exchange of fluids, solutes, plasma proteins and leucocytes, by 
opening and closing the cell junctions composing it in a coordinated manner [7]. The normal 
vascular endothelium consists of a layer of endothelial cells (ECs), supported on a basement 
membrane, with the glycocalyx on the luminal side [8]. It prevents microorganisms to enter into 
tissues, exerting in addition a natural anticoagulant action that prevents from uncontrolled 
activation of the coagulation system. 
 
Figure 1:The endothelium in different scenarios: A. Healthy endothelium: the normal vascular 
endothelium consists of a layer of endothelial cells with the glycocalyx on the luminal side. It 
prevents microorganisms to enter into tissues, exerting in addition a natural anticoagulant action 
that prevents from uncontrolled activation of the coagulation system. B. ED induced by aging and 
chronic disease: senescence and the comorbidities preceding sepsis are associated to the presence of 
a chronic status of increased oxidative stress and inflammation, which induces glicocalyx 
degradation, apoptosis of endothelial cells, disassembly of endothelial cell junctions, and increased 
expression of molecules which promotes leukocyte adhesion to endothelial cells. In turn, these 
diseases induce a pro-coagulant and anti-fibrinolytic state with diminished activation of protein C 
and increased production of tissue factor. Decrease in the production of nitric oxyde by the 
endothelial nitric oxide synthase promotes platelet aggregation and adhesion. Finally, these diseases 
impair production and function of Endothelial Progenitor Cells, impairing endothelial regeneration. 
C. ED in sepsis: sepsis induces similar features of ED to those caused by aging and chronic diseases, 
inducing oxidative stress and inflammation, release of NETs and proteases by neutrophils, leading 
to fluid and cell leakage, hypotension, microvascular thrombosis, inadequate organ perfusion, organ 
failure and shock in the most severe cases. In addition, bacterial toxins can breach the endothelial 
barrier, by directly killing ECs, weakening the cytoskeleton within ECs, and breaking the junctions 
between ECs. Acute challenges such as the aggression induced by surgery, trauma or hypervolemia 
could contribute to facilitate or enhance ED in patients facing an infection. Images for representing 
cells were taken from “Smart Servier Medical Art” (https://smart.servier.com/). 
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3.1 Glycocalyx (GCX): it is an organized layer of sulfated proteoglycans, hyaluronan, glycoproteins, 
and plasma proteins that adhere to a surface matrix which coats the luminal surface of the 
endothelium. It serves as a protective barrier between the flowing blood and the vessel wall, 
contributing to maintain the endothelial barrier to fluid and protein, to regulate 
leukocyte-endothelial adhesion and to inhibit intravascular thrombosis [9].  
3.2 Endothelial cells (ECs): ECs line our vasculature, as a one continuous layer resting on a basement 
membrane formed by collagen, laminins, nidogens/entactins, and the proteoglycan perlecan. 
Endothelial cells lining the vessel wall are connected by adherens junctions (mainly composed of 
vascular endothelial (VE)-cadherin, tight junctions (predominantly consisting of occludins and 
claudins) and gap junctions [2] [10], which prevent leukocyte emigration and vascular leak [2]. 
Embedded in the basement membrane and outside it is a non-continuous layer of cells known as 
pericytes, which are thought to play a role in angiogenesis [8]. 
4. ED in sepsis  
Sepsis causes acute ED, inducing a pro-adhesive, pro-coagulant and anti-fibrinolytic state in ECs, 
altering hemostasis, leukocyte trafficking, inflammation, barrier function, and microcirculation [11] 
(Figure 1).  
4.1 Increased oxidative stress and systemic inflammation: there are a number of mediators participating in 
the "molecular storm" occurring in sepsis that initiate and amplify injury to the endothelium. 
Between these molecules are bacterial endotoxins / pathogen-associated molecular patterns 
(PAMPs),  cytokines, bradykinin, histamine, platelet-activating factor (PAF), vascular endothelial 
growth factor (VEGF), fibrin degradation products and reactive oxygen species (ROS) such as 
hydrogen peroxide, hydroxyl anions, and superoxide [3] [12] [13] [14]. In turn, the endothelium it is 
not just a passive element suffering the aggression during sepsis, but it also produces chemokines to 
attract immune cells, boosting the inflammatory response [14].  
4.2 GCX degradation and shedding: the "cocktail" of pro-inflammatory and pro-oxydative molecules 
induced by sepsis promotes shedding of the GCX [2] [3] [15]. Release of damage- associated 
molecular patterns (DAMPs) such as degradation products of the endothelial GCX (i.e heparan 
sulfates) or components of Neutrophil extracellular traps (NETs) amplifies this deleterious response 
[9] [15].  
4.3 Disassembly of intercellular junctions, endothelial cell death, blood–tissue barrier disruption: the marked 
pro-inflammatory and oxidative response occurring in sepsis induces also the formation of gaps 
between ECs by disassembly of intercellular junctions [2] [3] [15]. NETs released from dying 
neutrophils induce death of ECs, an effect mediated by NETs-related proteases and cationic proteins 
such as defensins and histones [11] [16]. Bacterial toxins can breach the endothelial barrier, by 
directly killing ECs, weakening the cytoskeleton within ECs, and breaking the junctions between 
ECs [13].  
4.4 Enhanced leukocyte adhesion and extravasation: Glycocalyx shedding exposes the endothelium to 
leukocyte adhesion [15]. Pro-inflammatory cytokines induce expression of molecules such as 
P-selectin, E-selectin, ICAM1 or VCAM1 that allow adhesion of activated immune cells to the 
vascular wall and promote transendothelial migration into surrounding tissues [3]. Activated 
neutrophils from sepsis patients adhered to endothelium mediate profound loss of endothelial 
barrier integrity [17]. The proteases released by activated neutrophils could contribute to degrade 
junctional proteins [8]. Extravased neutrophils induce tissue damage producing potentially 
destructive enzymes and oxygen-free radicals.  
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4.5 Induction of a pro-coagulant and anti-fibrinolytic state: in sepsis there is also a global increase in the 
production of nitric oxide (NO, a potent vasodilator) mediated by the inducible nitric oxide synthase 
(iNOS) [3] [18]. In contrast, there is an important decrease in the production of NO by endothelial 
nitric oxide synthase (eNOS), which impairs direct vasodilatation, and promotes platelet and 
leukocyte adhesion [12]. Down-regulation of endothelial expression of thrombomodulin and 
endothelial protein C receptors translates into diminished activation of the activated protein C [11]. 
ECs release the procoagulant glycoprotein TF (tissue factor), whereas their synthesis of TF pathway 
inhibitor is inhibited [11]. The activation of platelets & the coagulation cascade causes microvascular 
thrombosis [9]. In addition, NETs provide a scaffold for thrombus formation, promoting 
hypercoagulability in patients with sepsis [11]. The association of TF with NETs could target 
thrombin generation and fibrin clot formation at sites of infection/neutrophil activation, with active 
thrombin leading to increased platelet activation [19]. Acute vascular dysfunction and leakage 
contribute to hypotension, inadequate organ perfusion, local hypoxia, ischemia and ultimately, to 
organ failure, acute respiratory distress syndrome, shock and death in the most severe patients [12] 
5. ED associated to aging and chronic disease. 
The same features of ED induced by sepsis are also induced by aging and chronic disease (Figure 1): 
5.1  Increased oxidative stress and systemic inflammation: aging is characterized by the presence of 
increased endothelial oxidative stress, as a result of augmented production from the intracellular 
enzymes NADPH oxidase and uncoupled eNOS, as well as from mitochondrial respiration in the 
absence of appropriate increases in antioxidant defenses [20]. Nitroso-oxydative stress contributes to 
ED associated with diabetes [21]. Vascular oxidative stress and inflammation are major determinants 
of ED in atherosclerosis and cardiovascular diseases [22]. Inflammation and free radical formation 
contributes also to the pathogenesis of hypertension and cancer [23]. In patients with Chronic 
Obstructive Pulmonary Disease (COPD), chronic inflammation does not impact only on lung 
parenchyma, but potentially involves the endothelium of blood vessels, which makes it a systemic 
disease [24]. Inflammation and oxidative stress play major roles in the pathogenesis of ED in liver 
cirrhosis [25].  
5.2 GCX degradation and shedding: untreated hypertension, diabetes mellitus and 
hypercholesterolemia are associated to a reduced endothelial GCX thickness [26] [27] [28]. 
Hyperglycaemia and oxidised low-density lipoprotein (LDL) causes GCX dysfunction [29]. GCX 
degradation is an initial event in atherosclerosis, promoting lipid deposition in the vessel wall [30]. 
Patients with chronic renal disease under dialysis have an impaired GCX barrier and shed its 
constituents into blood [31]. Cigarettes smoking (the main cause of COPD) compromises endothelial 
GCX integrity [32]. Patients with end-stage liver disease show marked increased concentration of 
syndecan-1 in plasma, a marker of GCX shedding [33]. Elevated haematocrit, a risk factor for stroke 
and myocardial infarction, could induce a reduction in GCX thickness [34]. Patients with heart 
failure with reduced ejection fraction have increased levels of the GCX shedding marker median 
hyaluronic acid [35]. Lacunar stroke patients with white matter lesions show compromised GCX 
barrier properties [36].  
5.3 Disassembly of intercellular junctions, endothelial cell death, blood–tissue barrier disruption: sedentary 
aging enhances endothelial cell senescence. Senescent ECs show a pro-oxidant phenotype with 
increased ROS production, which promote endothelial injury [20]. Tight junction structure and 
barrier integrity is significantly impaired in senescent ECs [37]. LDL from patients with 
hypercholesterolaemia are inflammatory to microvascular endothelial cells, impairing in addition 
endothelial tight junction expression [38]. Activation of endothelial inflammasomes due to increased 
free fatty acids produces high mobility group box protein-1, HMGB1, which disrupts 
inter-endothelial junctions and increases paracellular permeability of endothelium [39]. High 
glucose concentrations induce disruption of endothelial adherens junctions mediated by protein 
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kinase C-β-dependent vascular endothelial cadherin tyrosine phosphorylation [40]. Patients with 
chronic kidney diseases have increased levels of anti-endothelial cell antibodies, and decreased 
expression of both adherens and tight junction proteins VE-cadherin, claudin-1, and zonula 
occludens-1 [41]. Cigarette smoking disrupts intercellular adhesion molecules between ECs and 
induces their apoptosis [42]. In COPD patients, circulating anti-endothelial cell antibodies along 
with chronic oxidative and inflammatory stress induces apoptosis of ECs [43]. Cancer induces also 
disruption of endothelial junctions, in particular adherens junctions [44]. Anticancer chemotherapy 
may induce systemic damage of vascular endothelium related to massive cell loss and alterations of 
endothelial function [45]. Radiotherapy causes premature senescence, apoptosis of endothelial cells 
and increased vascular permeability [46] . Endothelial barrier is also altered in cardiovascular 
disease. Chemical modification of tubulin caused by cardiometabolic risk factors and oxidative 
stress leads to reorganization of endothelial microtubules, destabilizing vascular integrity and 
increasing permeability, which finally results in increasing cardiovascular and cerebrovascular risk 
[47] . Intravascular albumin is important to maintain vascular integrity, since it contributes to 
preserve normal capillary permeability [48] and the GCX structure [49]. Patients with malnutrition, 
liver disease or nephrotic syndrom could present hypo-albuminemia.  
5.4 Enhanced leukocyte adhesion and extravasation: aging is associated to stiffening of extracellular 
matrix within the intima, which promotes EC permeability and leukocyte extravasation [50]. 
Hypertension induces vascular wall injury and remodeling, a process which involves recruitment of 
leukocytes to the endothelium [23]. Glycocalix degradation in atherosclerosis facilitates the 
interaction between ECs and leukocytes [30]. Hyperglycemia induces activation of NF-κB in ECs, 
leading to an increased production of adhesion molecules, leukocyte-attracting chemokines and 
cytokines activating inflammatory cells in the vascular wall [51] . In chronic kidney disease, 
leukocytes acquire an adhesive phenotype, by mechanisms mediated by hypoxia and by cytokines 
released from ischemic renal endothelium [52]. In patients with COPD, fibrinogen is increased and 
stimulates the adhesion of platelets and white blood cells to the vessel wall [24]. Tobacco nicotine 
causes a loss of functional integrity of endothelium by causing vasospasm, stimulating the adhesion 
of leukocytes [53]. Up-regulation of selectins seems to be a central event in metastatic progression in 
cancer, proteins which mediate tethering and rolling of leukocytes to the vascular endothelium. 
Regarding cancer treatment, radiotherapy leads to increased endothelial cell activation and  
expression of VCAM-1, ICAM-1, PECAM-1, E-selectin and P-selectin, which promotes adhesion of 
leukocytes [46]. Chronic liver disease is characterized by upregulation of endothelium-adhesion 
molecules such as CD11b in circulating leukocytes in blood [54]. Leukocyte activation, adhesion and 
accumulation in the endothelium are events playing an important role in the pathogenesis of 
different cardiac diseases (myocarditis, cardiomyopathy, cardiac hypertrophy and failure, and 
ischemic heart disease) [55] and in ischemic cerebrovascular disease [56].   
5.5 Induction of a pro-coagulant and anti-fibrinolytic state: senescent ECs show reduced eNOS activity, 
which impairs their ability to inhibit platelet aggregation [57]. Hypertension is associated to ED 
leading to attenuated NO formation because of direct oxidative modification of eNOS [58]. GCX 
degradation in atherosclerosis causes ECs to reduce their expression of eNOS [30]. Oxidative stress 
associated with hyperglicemia induces eNOS uncoupling and reduce NO production [21]. 
Hyperglycemia, excess free fatty acid release and insulin resistance in diabetes mellitus induces 
platelet hyperactivity [51]. Hyperglycemia generates also a prothrombotic state by the increased 
production of lesion-based coagulants, such as tissue factor, and the inhibitors of fibrinolysis, such 
as PAI-1 [51]. Patients with chronic renal disease can show either coagulation defects and 
endothelial cell damage leading to a thrombophilic state, which is characterized by the presence of 
high plasma concentration of fibrinogen, D-dimer, thrombin–antithrombin complex, coagulation 
factor VII, vWF, thrombomodulin and PAI-1[59]. Patients with COPD or liver cirrhosis have 
impaired eNOS activity also [24] [25]. Smoking along with the mantained pro-inflammatory state in 
COPD induce a thrombotic effect, by increasing platelet activation and triggering coagulation 
cascade [24]. Cancer may result in activation of coagulation and endothelial cell perturbation, 
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leading to coagulopathies, a prothrombotic state and microvascular dysfunction, by mechanisms 
involving tissue factor-mediated thrombin generation, down regulation of endothelial 
cell-associated physiological anticoagulant pathways, deranged fibrinolysis and dysfunctional ECs 
[60]. This pro-coagulating phenotype in cancer could be favored also by chemo and radiotherapy 
[46] [60]. Patients with chronic liver disease show hyperhomocysteinaemia, a disorder of methionine 
metabolism, which has been suggested to cause endothelial injury and atherothrombotic vascular 
disease by several mechanisms involving oxidative stress, altered production of NO and impaired 
platelet-modulating activity [61]. Coronary heart disease associated with hypertension is 
characterized by reduced endothelial NO synthesis [62]. Endothelial dysfunction and coagulation 
are also involved in the pathogenesis of ischaemic stroke [63].  
6. Impact of aging and chronic disease on the mechanisms of endothelial repair   
Endothelial cell injury is mitigated by the reparative activity of bone marrow-derived endothelial 
progenitor cells (EPCs). As recently described, EPCs could have a role in determining the prognosis 
of patients with sepsis [64]. Chronic diseases preceding sepsis decrease EPC availability and/or 
mobilization. Cell senescence impairs the regenerative capacity of ECs. Age impairs migration of 
endothelial progenitor cells (EPCs) reducing their ability to contribute to vascular repair [65]. The 
absolute number, or functional capacity of EPCs, has been shown to be reduced in several disease 
states including diabetes, hypertension, hypercholesterolemia, and chronic kidney disease [66]. 
Circulating EPCs from COPD are dysfunctional, displaying impaired angiogenic ability and 
increased apoptosis [67]. Radiotherapy lower the number of circulating EPCs in cancer survivors 
[68]. The consequences of chemotherapy on EPCs at the long term are unknown. 
7. Discussion 
The evidence available from the literature shows that sepsis and their preceding risk factors (aging 
and chronic diseases) share common features of ED. In addition, aging and chronic diseases impair 
the regenerative ability of the endothelium. All of this draws a scenario of “endothelial frailty” 
preceding sepsis. Most of the features of ED are redundant in aging and the different chronic 
co-morbidities preceding sepsis, which could exert synergistic effects impairing endothelial function 
before and during sepsis. In addition, acute challenges such as the aggression induced by surgery, 
trauma or hypervolemia [69] [70] could contribute to facilitate or to enhance ED in patients facing an 
infection. In consequence, a phenomenon of acute on chronic ED could be occurring in sepsis, 
similar to the “acute on chronic kidney failure” of those patients with chronic renal disease (Figure 
1).  
A limitation of our review is that it was focused in those co-morbidities linked to sepsis in high 
income countries. In low-middle income countries, the epidemiological profile of sepsis is different. 
Sepsis patients are younger in these countries, but they suffer frequently from a number of 
conditions also linked to ED, such as malnutritition, malaria and HIV infection. Another limitation is 
that our review addresses only vascular ED. There is a total lack of information in the literature on 
the impact of sepsis, aging and chronic disease on the lymphatic vessels endothelium. The lymphatic 
system could have important implications in sepsis physiopathology, since it is the main avenue for 
circulation of dendritic cells and lymphocytes. Finally, studies evaluating the interactions between 
chronic endothelial, immunological, coagulation and metabolic dysfunction will help to better 
understand the pathogenesis of sepsis (Figure 2). 
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Figure 2. Potentially synergistic factors contributing to sepsis. Blue circle: Immunological, 
coagulation or metabolic alterations previous to sepsis or induced by sepsis. Green circle: Chronic ED 
pre-sepsis caused by aging and chronic diseases. Orange circle: Acute ED induced by sepsis 
secondary to microbial aggression, to the dysfunctional host response to infection, hypervolemia, 
trauma, surgery, and/or to other acute insults facilitating sepsis.   
8. Conclusions 
Sepsis, aging and chronic disease induce similar features of ED. The degree of ED already present 
prior to sepsis could have an important role in the pathogenesis of this disease. 
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